Mid-Year Oncology Review 2025: History Informs the Future

What are the promises and limitations of different therapeutic modalities in solid tumors? As we approach the mid-year point, we reflect on the advancements in oncology in recent years.

Ipsos Mid Year Oncology Review 2025 - History Informs the FutureIpsos explores challenges and opportunities in the development of emerging therapeutic modalities aimed at addressing solid tumors as well as prominent topics in the field including the dominance of small molecules as a time-tested and well-established modality that nonetheless continues to lead in FDA approval numbers each year; the potential of cancer vaccines to break through to the forefront owing to the opportunities created by mRNA-based neoantigens; and the journey of cell therapies as they start to penetrate solid tumor applications. 

In this white paper, supported by Ipsos’ survey of oncologists based in the US, as well as KOL interviews, we reveal 5 key themes in oncology and how past lessons inform the innovations of today.

Sign up to access the white paper

The author(s)

More insights about Health

Related news

  • KEYS: Our World in Motion
    E mobility Events replay

    [Webinar] KEYS: Our World in Motion

    At our next KEYS webinar, we’ll be launching the inaugural Ipsos Mobility Report.
  • [Webinar] Real evidence from real experiences: Patient Centric Evidence
    Healthcare Webinar

    [Webinar] Real evidence from real experiences: Patient Centric Evidence

    Regulators, payers and clinicians are asking for more than traditional real world evidence (RWE). They want to understand how treatments affect people’s daily lives - not just what is written in the case report form. But how can you build patient-centric evidence that stands up to scientific, regulatory and commercial scrutiny?
  • Battle For Attention - KEYS Webinar from Ipsos
    Communications Events replay

    [Webinar] KEYS: Battle For Attention

    In today’s hyper-fragmented landscape, communicating using short-form content and social media platforms is an essential part of our toolkit. But are they better suited to short-term engagement rather than long-term brand building? And what does genuinely innovative and creative advertising look like these days?